Fatma Zgolli

Fatma Zgolli

Auto-generated profile, based on publicly available information

Fatma Zgolli

Service de Recueil et d’Analyse des Effets Indésirables, Centre National Chalbi BELKAHIA de Pharmacovigilance

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Therapies
Verified
Journal Article
Closed access
FZFatma Zgolli
Fatma Zgolli
OCOns Charfi
Ons Charfi
GLGhozlane Lakhoua
Ghozlane Lakhoua
SASihem El Aidli
Sihem El Aidli
IAImen Aouinti
Imen Aouinti
AZAhmed Zaiem
Ahmed Zaiem

20 February 2026 in American Journal of Therapeutics
Verified
Journal Article
Closed access
IFIkram Fazaa
Ikram Fazaa
FZFatma Zgolli
Fatma Zgolli
RORihab Ouerghi
Rihab Ouerghi
IYInsaf Ben Yaiche
Insaf Ben Yaiche
NANour Ben Abdeljelil
Nour Ben Abdeljelil
SASihem Aidli
Sihem Aidli

17 September 2020
Verified
Preprint
Open access
FZFatma Zgolli
Fatma Zgolli
IAImen Aouinti
Imen Aouinti
OCOns Charfi
Ons Charfi
SKSarrah Kastalli
Sarrah Kastalli
RDRiadh Daghfous
Riadh Daghfous
GLGhozlane Lakhoua
Ghozlane Lakhoua
Fatma Zgolli 1 2, Imen Aouinti 1 2, Ons Charfi1 2, Sarrah Kastalli1 2, Daghfous Riadh1 2, Sihem EL Aidli 1 2, Ghozlane Lakhoua 1 21National Center Chalbi Belkahia of Pharmacovigilance, 9 Avenue du Dr Zouhaier Essafi 1006, Tunis, Tunisia.2University o

3 March 2023
Verified
Preprint
Open access
PDF file
ISInes Souilem
Ines Souilem
OCOns Charfi
Ons Charfi
IHImen Hamza
Imen Hamza
FZFatma Zgolli
Fatma Zgolli
SKSarrah Kastalli
Sarrah Kastalli
SASihem El Aidli
Sihem El Aidli
Background: Sofosbuvir, a very effective new direct-acting antiviral agent (DAA), has revolutionized the therapeutic management of people infected with hepatitis C virus. It has a low reported rate of side effects. Leukocytoclastic vasculitis can be associated with hepatitis C but can also be induced by many drugs. We describe a case of leucocytoclasic vasculitis induced by Sofosbuvir that resolved 3 days after drug withdrawal. We observed a temporal relationship between the treatment and the onset of vasculitis. We emphasize the multidisciplinary approach to patients with hepatitis C to make the difference between drug-induced skin damage and damage caused by the virus itself. Case presentation: A 61-year-old woman, with a history of hepatitis C virus infection started treatment with the combination ledipasvir sofosbuvir in June 2020, 400 mg per day. Five weeks later, she developed a slightly itchy erythematous and symmetrical rash on lower members. The patient initially suspected the treatment and she stopped it. Histological finding revealed a diffuse neutrophile infiltration of vessel walls confirming leukocytoclastic vasculitis. These lesions disappeared completely three days after drug withdrawal without any symptomatic treatment. Conclusions: Sofosbuvir is one of the several recent drugs that should be prone to further attention.

9 July 2026 in Therapies
Verified
Journal Article
Closed access
FZFatma Zgolli
Fatma Zgolli
WDWiem Daly
Wiem Daly
IAImen Aouinti
Imen Aouinti
IDIsraa Dahmani
Israa Dahmani
HHHela Haouet
Hela Haouet
SASihem El Aidli
Sihem El Aidli